PT3354751T - Anticorpos contra aripiprazole e seu uso - Google Patents

Anticorpos contra aripiprazole e seu uso

Info

Publication number
PT3354751T
PT3354751T PT181612623T PT18161262T PT3354751T PT 3354751 T PT3354751 T PT 3354751T PT 181612623 T PT181612623 T PT 181612623T PT 18161262 T PT18161262 T PT 18161262T PT 3354751 T PT3354751 T PT 3354751T
Authority
PT
Portugal
Prior art keywords
aripiprazole
antibodies
Prior art date
Application number
PT181612623T
Other languages
English (en)
Inventor
Salter Rhys
Hryhorenko Eric
R Decory Thomas
M Remmerie Bart
Sankaran Banumathi
Tubbs Theresa
Colt Linda
Lin Ronghui
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT3354751T publication Critical patent/PT3354751T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT181612623T 2012-08-21 2013-08-20 Anticorpos contra aripiprazole e seu uso PT3354751T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261691522P 2012-08-21 2012-08-21

Publications (1)

Publication Number Publication Date
PT3354751T true PT3354751T (pt) 2019-12-17

Family

ID=50148307

Family Applications (2)

Application Number Title Priority Date Filing Date
PT181612623T PT3354751T (pt) 2012-08-21 2013-08-20 Anticorpos contra aripiprazole e seu uso
PT138303755T PT2888373T (pt) 2012-08-21 2013-08-20 Anticorpos contra aripiprazole e seu uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT138303755T PT2888373T (pt) 2012-08-21 2013-08-20 Anticorpos contra aripiprazole e seu uso

Country Status (11)

Country Link
US (3) US9494607B2 (pt)
EP (3) EP2888373B1 (pt)
JP (2) JP6270845B2 (pt)
CN (2) CN104755631B (pt)
AU (3) AU2013305879B2 (pt)
CA (1) CA2882562C (pt)
ES (2) ES2666000T3 (pt)
HK (2) HK1211989A1 (pt)
PL (2) PL3354751T3 (pt)
PT (2) PT3354751T (pt)
WO (1) WO2014031640A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3462173T3 (pl) 2012-08-21 2021-08-16 Janssen Pharmaceutica Nv Przeciwciała przeciwko rysperydonowi i ich zastosowanie
PL2888284T3 (pl) 2012-08-21 2023-02-27 Janssen Pharmaceutica Nv Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
ES2664952T3 (es) 2012-08-21 2018-04-24 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
CN106928369B (zh) 2012-08-21 2021-04-02 奥索临床诊断有限公司 喹硫平的抗体及其用途
PT2887952T (pt) 2012-08-21 2019-08-30 Janssen Pharmaceutica Nv Anticorpos para haptenos da olanzapina e suas utilizações
EP2888590B1 (en) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
EP3390449A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica N.V. Antibodies to risperidone and use thereof
US10483164B2 (en) * 2017-11-14 2019-11-19 Taiwan Semiconductor Manufacturing Company Ltd. Semiconductor structure and method for manufacturing the same
EP3805251A4 (en) * 2018-06-06 2022-03-16 National Institute Of Advanced Industrial Science And Technology METHOD FOR EFFICIENT INDUCTION OF ANTIBODIES TO HEPATITIS VIRUS, ANTIBODIES AND DETECTION SYSTEM
WO2021236724A2 (en) * 2020-05-20 2021-11-25 Remd Biotherapeutics, Inc. Human endothelin receptor a (etar) antagonist antibodies

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
EP0291194B8 (en) 1987-04-27 2003-10-22 Inverness Medical Switzerland GmbH Immunoassays and devices therefor
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
PT582368E (pt) 1992-05-29 2001-05-31 Lilly Co Eli Derivados de tienobenzodiazepina para o tratamento de doencas de cns
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5527709A (en) 1992-06-26 1996-06-18 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays with labeled thyronine hapten analogues
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
JPH07247271A (ja) 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
CA2192467C (en) * 1994-06-10 2009-03-31 Alireza Rezaie Calcium binding recombinant antibody against protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US6139800A (en) 1997-06-23 2000-10-31 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
UA76708C2 (uk) 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US20030202975A1 (en) 2002-02-21 2003-10-30 Tedder Thomas F. Reagents and treatment methods for autoimmune diseases
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
IL163852A0 (en) 2002-03-01 2005-12-18 Immunomedics Inc Rs7 antibodies
DE60318030T2 (de) 2002-03-28 2008-04-10 Eli Lilly And Co., Indianapolis Piperazine-substituierte aryl-benzodiazepine und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychosen
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
JP2005538108A (ja) 2002-07-29 2005-12-15 ポトマック， ファーマ， エルエルシー α−２アドレナリン作動性レセプターアンタゴニストと非定型抗精神病薬精神安定薬との抗精神病薬組み合わせ治療および組成物
PT1546134E (pt) 2002-08-05 2007-08-10 Lilly Co Eli ''arilbenzodiazepinas substituídas com piperazina''
NZ568403A (en) 2003-05-09 2009-10-30 Univ Duke CD20-specific antibodies and methods of employing same
BRPI0413555A (pt) 2003-08-18 2006-10-17 Lundbeck & Co As H composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, método para o tratamento de uma doença, para a fabricação de um composto e para a preparação de composto
DE602004024798D1 (de) 2003-09-23 2010-02-04 Fermion Oy Herstellung von quetiapin
AU2004278414B2 (en) 2003-10-01 2012-05-24 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
CA2548164C (en) 2003-12-12 2013-10-08 Inverness Medical Switzerland Gmbh Assay kit for detecting analytes of interest in samples
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
EP1748070A4 (en) 2004-04-26 2007-07-18 Takami Matsuyama THERAPEUTIC WITH MONOCLONAL ANTIBODY AGAINST FOLAT RECEPTOR BETA (FR-BETA)
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7658991B2 (en) * 2004-10-21 2010-02-09 University Of Georgia Research Foundation, Inc. Structures having aligned nanorods and methods of making
US7837726B2 (en) * 2005-03-14 2010-11-23 Abbott Laboratories Visible endoprosthesis
US20070255094A1 (en) * 2005-03-14 2007-11-01 Oepen Randolf V Crack/fatigue resistant endoprosthesis
US20060235005A1 (en) * 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
ZA200708857B (en) * 2005-04-22 2009-01-28 Genentech Inc Method for treating dementia or alzheimer's disease with a CD30 antibody
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
ES2405364T3 (es) 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
EP2198309A1 (en) 2007-09-27 2010-06-23 Novartis Ag Drug monitoring assay
US8133743B2 (en) 2007-10-19 2012-03-13 Roche Diagnostics Operations, Inc. Phenobarbital derivatives useful in immunoassay
EP3338796A1 (en) 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
AU2009279372A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
EA201100613A1 (ru) 2008-10-14 2011-12-30 Астразенека Аб Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
JP2012507297A (ja) 2008-10-29 2012-03-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｅｒｂｂ４遺伝子の多型に基づく精神病及び統合失調症の治療法
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
US20100203129A1 (en) 2009-01-26 2010-08-12 Egalet A/S Controlled release formulations with continuous efficacy
EP3138854B1 (en) * 2009-03-10 2022-01-26 Baylor Research Institute Antibodies against cd40
WO2010151711A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
LT2459220T (lt) 2009-07-31 2020-12-28 Ascendis Pharma A/S Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu
US8076097B2 (en) 2009-08-19 2011-12-13 Saladax Biomedical Inc. Imatinib immunoassay
EP2485767A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
LT2544536T (lt) 2010-03-11 2019-02-25 Kempharm, Inc. Kvetiapino riebalų rūgšties konjugatai, jų gamybos būdas ir panaudojimas
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
CN102260290A (zh) 2010-05-25 2011-11-30 苏州波锐生物医药科技有限公司 喹喏啉酮类化合物及其在制备精神病药物中的用途
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2011163594A2 (en) 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2012003418A2 (en) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
AU2012296950B2 (en) 2011-08-12 2016-09-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
MX2015002036A (es) 2012-08-16 2016-01-22 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
JP6131500B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドン及びパリペリドンのハプテン
PL3462173T3 (pl) 2012-08-21 2021-08-16 Janssen Pharmaceutica Nv Przeciwciała przeciwko rysperydonowi i ich zastosowanie
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
PT2887952T (pt) 2012-08-21 2019-08-30 Janssen Pharmaceutica Nv Anticorpos para haptenos da olanzapina e suas utilizações
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
CN106928369B (zh) 2012-08-21 2021-04-02 奥索临床诊断有限公司 喹硫平的抗体及其用途
JP6131415B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． イムノアッセイに使用するためのクエチアピンのハプテン
PT2888258T (pt) 2012-08-21 2019-08-21 Janssen Pharmaceutica Nv Hapteno de paliperidona
PL2888284T3 (pl) 2012-08-21 2023-02-27 Janssen Pharmaceutica Nv Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
EP2888590B1 (en) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
ES2701062T3 (es) 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
ES2664952T3 (es) 2012-08-21 2018-04-24 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Also Published As

Publication number Publication date
PL2888373T3 (pl) 2018-08-31
HK1260330A1 (zh) 2019-12-20
WO2014031640A2 (en) 2014-02-27
EP3663316A1 (en) 2020-06-10
EP2888373B1 (en) 2018-03-14
CN107325183B (zh) 2021-06-04
US10175257B2 (en) 2019-01-08
PT2888373T (pt) 2018-06-12
US20140057300A1 (en) 2014-02-27
PL3354751T3 (pl) 2020-03-31
CN104755631B (zh) 2017-09-05
ES2762105T3 (es) 2020-05-22
JP2018118961A (ja) 2018-08-02
CN107325183A (zh) 2017-11-07
JP2015531768A (ja) 2015-11-05
US20170030936A1 (en) 2017-02-02
EP3354751B1 (en) 2019-10-02
CA2882562A1 (en) 2014-02-27
EP2888373A4 (en) 2016-05-11
AU2019284031A1 (en) 2020-01-23
EP2888373A2 (en) 2015-07-01
ES2666000T3 (es) 2018-04-30
EP3354751A1 (en) 2018-08-01
AU2013305879A1 (en) 2015-03-05
US9494607B2 (en) 2016-11-15
CA2882562C (en) 2019-08-27
US20190128904A1 (en) 2019-05-02
JP6567033B2 (ja) 2019-08-28
US10816561B2 (en) 2020-10-27
HK1211989A1 (en) 2016-06-03
AU2018200278A1 (en) 2018-02-01
CN104755631A (zh) 2015-07-01
WO2014031640A3 (en) 2014-05-01
AU2019284031B2 (en) 2022-03-31
AU2018200278B2 (en) 2019-09-26
JP6270845B2 (ja) 2018-01-31
AU2013305879B2 (en) 2017-10-12
AU2018200278B9 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
HK1211989A1 (en) Antibodies to aripiprazole and use thereof
HK1255219A1 (zh) 喹硫平的抗體及其用途
HK1211955A1 (en) Antibodies to aripiprazole haptens and use thereof
HK1212034A1 (en) Antibodies to risperidone and use thereof
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
SG11201407099WA (en) Anti-pcsk9 antibodies and use thereof
SG10201708127UA (en) Anti-mcam antibodies and associated methods of use
HK1211958A1 (en) Antibodies to paliperidone and use thereof
HK1212033A1 (en) Antibodies to olanzapine and use thereof
GB201208372D0 (en) Antibodies and uses thereof